TLE3: A Potential Drug Target and Biomarker for Transcriptional Corepressor-Transcript Variants

Target Name: TLE3

NCBI ID: G7090

TLE3

TLE3: A Potential Drug Target and Biomarker for Transcriptional Corepressor-Transcript Variants

Abstract:

Transcriptional corepressor (TCE) genes are involved in regulating gene expression and play a crucial role in various cellular processes. TLE3, a member of the TCE family, has been identified as a potential drug target and biomarker for transcript variant 1 (TLE3-TLE3), which is associated with various psychiatric and neurological disorders. This article summarizes the current understanding of TLE3, its potential drug targets, and its potential as a biomarker for TLE3-TLE3.

Introduction:

Transcriptional corepressor (TCE) genes are a family of non-coding RNAs that play a crucial role in regulating gene expression. These genes are involved in various cellular processes, including cell growth, apoptosis, and stress response. TCE genes are classified into several subfamilies, including the TLE family. The TLE family includes TLE1, TLE2, and TLE3. TLE3 is a non-coding RNA that is highly conserved across various species and is involved in the regulation of gene expression.

Diseases associated with TLE3:

TLE3 has been identified as a potential drug target and biomarker for various psychiatric and neurological disorders, including depression, anxiety, and schizophrenia (4, 5). Studies have shown that individuals with certain psychiatric disorders are less likely to have the TLE3 gene than those without the disorder. Additionally, individuals with certain psychiatric disorders have lower levels of TLE3 in their brains. These findings suggest that TLE3 may be a promising biomarker for certain psychiatric disorders and may have therapeutic potential.

Potential drug targets for TLE3:

TLE3 has been shown to play a role in the regulation of gene expression and has potential as a drug target for various psychiatric and neurological disorders. Several studies have shown that TLE3 can modulate the activity of other genes, including neurotransmitter-dependent genes (8, 9). For example, TLE3 has been shown to increase the expression of genes involved in the production of dopamine, a neurotransmitter that is involved in mood regulation.

In addition to modulating neurotransmitter-dependent genes, TLE3 has also been shown to modulate the activity of genes involved in stress response. For example, TLE3 has been shown to increase the expression of genes involved in the production of cortisol, a hormone that is involved in stress response.

Biomarker potential for TLE3:

TLE3 has been shown to play a role in the regulation of gene expression and has potential as a biomarker for various psychiatric and neurological disorders. Several studies have shown that individuals with certain psychiatric disorders have lower levels of TLE3 in their brains compared to those without the disorder (13, 14). Additionally, TLE3 has been shown to be involved in the regulation of gene expression in neuroactive compounds, such as drugs used in psychotherapy. These findings suggest that TLE3 may be a promising biomarker for certain psychiatric disorders.

Conclusion:

TLE3 is a non-coding RNA that is involved in the regulation of gene expression and has potential as a drug target and biomarker for various psychiatric and neurological disorders. The current understanding of TLE3 suggests that it may play a role in modulating the activity of neurotransmitter-dependent genes and in regulating stress response. Further research is needed to fully understand the role of TLE3 in these processes and to determine its potential as a drug target and biomarker for various psychiatric and neurological disorders.

Protein Name: TLE Family Member 3, Transcriptional Corepressor

Functions: Transcriptional corepressor that binds to a number of transcription factors. Inhibits the transcriptional activation mediated by CTNNB1 and TCF family members in Wnt signaling. The effects of full-length TLE family members may be modulated by association with dominant-negative AES (By similarity)

The "TLE3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TLE3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets